NCT02707211

Anti-oxLDL IgM Antibodies as a Novel Therapy for Metabolic Lipid Diseases

Immunization Against oxLDL in Patients With Lysosomal Lipid Diseases and Associated Metabolic Disorders

• Status: Unknown
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Universitaire Ziekenhuizen KU Leuven · Academic / Other
• Sex: All
• Age: 2 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

To test whether active pneumococci immunization can alleviate inflammation and improve cholesterol metabolism in lysosomal lipid storage diseases and associated metabolic disorders.

Detailed description

Growing evidence describes the central role of oxidized low density lipoproteins (oxLDL) in diseases related to lipid metabolism. Moreover, oxLDL has been shown to be involved in pathological processes such as an inappropriate inflammatory response, disturbance of cholesterol metabolism and dysfunction of the lysosomal apparatus. Relevantly, it has been shown that immunizing mice with Streptococcus pneumoniae results in higher serum titers of anti-oxLDL IgM antibodies due to molecular mimicry.

Conditions

• Lipid Metabolism, Inborn Errors

Interventions

Type	Name	Description
BIOLOGICAL	Anti-oxLDL IgM antibody	Immunization

Timeline

• Start date: 2016-06-01
• Primary completion: 2017-02-01
• Completion: 2017-02-01
• First posted: 2016-03-14
• Last updated: 2016-03-15

Locations

1 site across 1 country: Belgium